2017
Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock
JANTTI, T., T. TARVASMAKI, V.P. HARJOLA, J. PARISSIS, K. PULKKI et. al.Základní údaje
Originální název
Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock
Autoři
JANTTI, T., T. TARVASMAKI, V.P. HARJOLA, J. PARISSIS, K. PULKKI, A. SIONIS, J. SILVA-CARDOSO, L. KOBER, M. BANASZEWSKI, Jindřich ŠPINAR, V. FUHRMANN, J. TOLONEN, V. CARUBELLI, S. DISOMMA, A. MEBAZAA a J. LASSUS
Vydání
American Journal of Cardiology, BRIDGEWATER, EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC, 2017, 0002-9149
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.171
Organizační jednotka
Lékařská fakulta
UT WoS
000412626000008
Klíčová slova anglicky
Cardiogenic Shock
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 15. 3. 2018 15:59, Soňa Böhmová
Anotace
V originále
Cardiogenic shock (CS) is a cardiac emergency often leading to multiple organ failure and death. Assessing organ dysfunction and appropriate risk stratification are central for the optimal management of these patients. The purpose of this study was to assess the prevalence of abnormal liver function tests (LFTs), as well as early changes of LFTs and their impact on outcome in CS. We measured LFTs in 178 patients in CS from serial blood samples taken at 0 hours, 12 hours, and 24 hours. The associations of LFT abnormalities and their early changes with all-cause 90-day mortality were estimated using Fisher's exact test and Cox proportional hazards regression analysis. Baseline alanine aminotransferase (ALT) was abnormal in 58% of the patients, more frequently in nonsurvivors. Abnormalities in other LFTs analyzed (alkaline phosphatase, gamma-glutamyl transferase, and total bilirubin) were not associated with short-term mortality. An increase in ALT of >20% within 24 hours (AALT>+20%) was observed in 24% of patients. AALT>+20% was associated with a more than 2-fold increase in mortality compared with those with stable or decreasing ALT (70% and 28%, p <0.001). Multivariable regression analysis showed that AALT>+20% was associated with increased 90-day mortality independent of other known" risk factors. In conclusion, an increase in ALT in the initial phase was seen in 1/4 of patients in CS and was independently associated with 90-day mortality. This finding suggests that serial ALT measurements should be incorporated in the clinical assessment of patients in CS. (C) 2017 Elsevier Inc. All rights reserved.